CoChat

Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms

Open access
Wada, Ryuta, Matsui, Makoto, Kawasaki, Nana · 2019 · mAbs

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.

Abstract

Glycosylation of the conserved asparagine residue in each heavy chain of IgG in the CH2 domain is known as N-glycosylation. It is one of the most common post-translational modifications and important critical quality attributes of monoclonal antibody (mAb) therapeutics. Various studies have demonstrated the effects of the Fc N-glycosylation on safety, Fc effector functions, and pharmacokinetics, both dependent and independent of neonatal Fc receptor (FcRn) pathway. However, separation of various glycoforms to investigate the biological and functional relevance of glycosylation is a major challenge, and existing studies often discuss the overall impact of N-glycans, without considering the individual contributions of each glycoform when evaluating mAbs with highly heterogeneous distributions. In this study, chemoenzymatic glycoengineering incorporating an endo-β-N-acetylglucosaminidase (ENGase) EndoS2 and its mutant with transglycosylation activity was used to generate mAb glycoforms with highly homogeneous and well-defined N-glycans to better understand and precisely evaluate the effect of each N-glycan structure on Fc effector functions and protein stability. We demonstrated that the core fucosylation, non-reducing terminal galactosylation, sialylation, and mannosylation of IgG1 mAb N-glycans impact not only on FcγRIIIa binding, antibody-dependent cell-mediated cytotoxicity, and C1q binding, but also FcRn binding, thermal stability and propensity for protein aggregation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/19420862.2018.1551044

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Generation of IgG1 glycoforms with homogeneous glycoforms. (a) IgG1 N-glycosylation schematics and abbreviations used in this study for elucidating structures of complex type biantennary N-glycan. Presence of a core fucose is indicated by F; Ax indicates a biantennary glycan structure with the number (x) of GlcNAc on the antenna; Gx indicates the number (x) of galactose on the antenna; Sx indicates the number (x) of sialic acid on the antenna. Fuc: Fucose, Man: Mannose, GlcNAc: N-Acetylglucosamine, Gal: Galactose, SA: Sialic Acid. (b) Each core fucosylated and non-fucosylated homogeneous glycoform was generated from the same CHO cell line with or without Kifunensine to produce starting mAbs, control (ctrl) and high-mannose (HM). Subsequent deglycosylation and transglycosylation performed to obtain resulting homogeneous glycoforms. Endoglycosidase EndoS2 from S. pyogenes and D184 mutant as glycosynthase recombinantly expressed from E. coli. Glycan oxazolines (oxa) were used as well-defined donor substrates (Figure S1).
Figure 1. Generation of IgG1 glycoforms with homogeneous glycoforms. (a) IgG1 N-glycosylation schematics and abbreviations used in this study for elucidating structures of complex type biantennary N-glycan. Presence of a core fucose is indicated by F; Ax indicates a biantennary glycan structure with the number (x) of GlcNAc on the antenna; Gx indicates the number (x) of galactose on the antenna; Sx indicates the number (x) of sialic acid on the antenna. Fuc: Fucose, Man: Mannose, GlcNAc: N-Acetylglucosamine, Gal: Galactose, SA: Sialic Acid. (b) Each core fucosylated and non-fucosylated homogeneous glycoform was generated from the same CHO cell line with or without Kifunensine to produce starting mAbs, control (ctrl) and high-mannose (HM). Subsequent deglycosylation and transglycosylation performed to obtain resulting homogeneous glycoforms. Endoglycosidase EndoS2 from S. pyogenes and D184 mutant as glycosynthase recombinantly expressed from E. coli. Glycan oxazolines (oxa) were used as well-defined donor substrates (Figure S1).CC BY-NC-ND · PubMed Central
Figure 2. Reduced Heavy chain LC-MS analysis of glycoforms. Deconvoluted mass spectrometric data of heavy chain of starting mAbs, acceptors and resulting six glycoforms are shown to confirm intended transglycosylation and good agreement with theoretical molecular mass shown in Table 2. Starting mAbs showed relatively heterogeneous mass spectrum, where resulting acceptors and transglycosylated glycoforms showed highly homogeneous profile. Truncation of one sialic acid residue observed for mAb-FA2G2S2 and mAb-A2G2S2 is possibly due to fragmentation induced by ionization. No alternations in light chain were observed by the reduced mass analysis (data not shown).
Figure 2. Reduced Heavy chain LC-MS analysis of glycoforms. Deconvoluted mass spectrometric data of heavy chain of starting mAbs, acceptors and resulting six glycoforms are shown to confirm intended transglycosylation and good agreement with theoretical molecular mass shown in Table 2. Starting mAbs showed relatively heterogeneous mass spectrum, where resulting acceptors and transglycosylated glycoforms showed highly homogeneous profile. Truncation of one sialic acid residue observed for mAb-FA2G2S2 and mAb-A2G2S2 is possibly due to fragmentation induced by ionization. No alternations in light chain were observed by the reduced mass analysis (data not shown).CC BY-NC-ND · PubMed Central
Figure 3. 2-AB labeled released N-glycan analysis of the transglycosylated glycoforms. N-glycans of heavy chain of the transglycosylated glycoforms were enzymatically released by PNGaseF and labelled by 2-AB for fluorescent detection in the HILIC mode separation to confirm the intended enrichment of N-glycans. Relative peak abundance of each glycoform was also described in Table 1, showing over 90% homogeneity for all transglycosylated glycoforms generated.
Figure 3. 2-AB labeled released N-glycan analysis of the transglycosylated glycoforms. N-glycans of heavy chain of the transglycosylated glycoforms were enzymatically released by PNGaseF and labelled by 2-AB for fluorescent detection in the HILIC mode separation to confirm the intended enrichment of N-glycans. Relative peak abundance of each glycoform was also described in Table 1, showing over 90% homogeneity for all transglycosylated glycoforms generated.CC BY-NC-ND · PubMed Central
Figure 4. Binding affinity of FcγRIIIa was increased by core defucosylation and terminal galactosylation, decreased by further terminal sialylation in SPR analysis. (a) Sensorgrams of each glycoform. Anti-His Ab was immobilized on CM5 chip. N-terminal his tagged FcγRIIIa captured and glycoforms as analytes were injected by single-cycle mode at five concentrations. (b) Relative binding activities of FcγRIIIa. Error bars represent SD of n = 3 and asterisks indicate statistical significance at p < 0.05. n.d: not determined. (c) JMP analysis: Scaled estimates of effect of glycosylation for binding affinity of FcγRIIIa. Analyzed for complex biantennary glycoforms. (d) JMP analysis: Interaction profile of terminal glycosylation for binding affinity of FcγRIIIa. Analyzed for complex biantennary glycoforms. In lower left panel, red: Gal, blue: SA, and green: GlcNAc. Significant statistical interaction between core fucosylation and terminal galactosylation (c-d).
Figure 4. Binding affinity of FcγRIIIa was increased by core defucosylation and terminal galactosylation, decreased by further terminal sialylation in SPR analysis. (a) Sensorgrams of each glycoform. Anti-His Ab was immobilized on CM5 chip. N-terminal his tagged FcγRIIIa captured and glycoforms as analytes were injected by single-cycle mode at five concentrations. (b) Relative binding activities of FcγRIIIa. Error bars represent SD of n = 3 and asterisks indicate statistical significance at p < 0.05. n.d: not determined. (c) JMP analysis: Scaled estimates of effect of glycosylation for binding affinity of FcγRIIIa. Analyzed for complex biantennary glycoforms. (d) JMP analysis: Interaction profile of terminal glycosylation for binding affinity of FcγRIIIa. Analyzed for complex biantennary glycoforms. In lower left panel, red: Gal, blue: SA, and green: GlcNAc. Significant statistical interaction between core fucosylation and terminal galactosylation (c-d).CC BY-NC-ND · PubMed Central
Figure 5. FcγRIIIa affinity chromatography showed longer retention by core fucosylation, terminal galactosylation and further sialylation. Non-glycosylated recombinant FcγRIIIa prepacked column was used to analyze the affinity interaction between transglycosylated glycoforms.
Figure 5. FcγRIIIa affinity chromatography showed longer retention by core fucosylation, terminal galactosylation and further sialylation. Non-glycosylated recombinant FcγRIIIa prepacked column was used to analyze the affinity interaction between transglycosylated glycoforms.CC BY-NC-ND · PubMed Central
Figure 6. ADCC activity was increased by core defucosylation and terminal galactosylation, decreased by further sialylation in reporter bioassay for FcγRIIIa. Nuclear factor of activated T-cells (NFAT) engineered Jurkat cells expressing FcγRIIIa were incubated with target antigen expressing CHO-K1 cells. Receptor binding activates gene transcription through the NFAT pathway in effector cell leading to luciferase production and subsequent luciferase substrate addition was followed by luminescence detection. (a) Response curves of mAb-ctrl and fucosylated glycoforms. (b) Response curves of mAb-ctrl and non-fucosylated glycoforms. (c) Relative binding activity from EC50 of glycoforms. n.d: not determined. (d) JMP analysis: scaled estimates of effect of glycosylation for ADCC activity. Analyzed for complex biantennary glycoforms. (e) JMP analysis: Interaction profile of terminal glycosylation for ADCC activity. Analyzed for complex biantennary glycoforms. In lower left panel, red: Gal, blue: SA, and green: GlcNAc. Significant statistical interaction between core fucosylation and terminal galactosylation (d-e). Error bars represent 95% confidence interval of n = 3 (a-c).
Figure 6. ADCC activity was increased by core defucosylation and terminal galactosylation, decreased by further sialylation in reporter bioassay for FcγRIIIa. Nuclear factor of activated T-cells (NFAT) engineered Jurkat cells expressing FcγRIIIa were incubated with target antigen expressing CHO-K1 cells. Receptor binding activates gene transcription through the NFAT pathway in effector cell leading to luciferase production and subsequent luciferase substrate addition was followed by luminescence detection. (a) Response curves of mAb-ctrl and fucosylated glycoforms. (b) Response curves of mAb-ctrl and non-fucosylated glycoforms. (c) Relative binding activity from EC50 of glycoforms. n.d: not determined. (d) JMP analysis: scaled estimates of effect of glycosylation for ADCC activity. Analyzed for complex biantennary glycoforms. (e) JMP analysis: Interaction profile of terminal glycosylation for ADCC activity. Analyzed for complex biantennary glycoforms. In lower left panel, red: Gal, blue: SA, and green: GlcNAc. Significant statistical interaction between core fucosylation and terminal galactosylation (d-e). Error bars represent 95% confidence interval of n = 3 (a-c).CC BY-NC-ND · PubMed Central
Figure 7. Binding affinity of C1q increased by terminal galactosylation and sialylation. (a) Sensorgrams of each glycoform. Glycoforms were first captured on Protein A chip and C1q as analytes were injected by multi-cycle mode at eight concentrations. Sensorgrams were fitted with steady-state equilibrium model. (b) Relative binding activities of C1q. Error bars represent SD of n = 3 and asterisks indicate statistical significance at p < 0.05. (c) JMP analysis: Scaled estimates of effect of glycosylation for binding affinity of C1q. Analyzed for complex biantennary glycoforms and acceptors.
Figure 7. Binding affinity of C1q increased by terminal galactosylation and sialylation. (a) Sensorgrams of each glycoform. Glycoforms were first captured on Protein A chip and C1q as analytes were injected by multi-cycle mode at eight concentrations. Sensorgrams were fitted with steady-state equilibrium model. (b) Relative binding activities of C1q. Error bars represent SD of n = 3 and asterisks indicate statistical significance at p < 0.05. (c) JMP analysis: Scaled estimates of effect of glycosylation for binding affinity of C1q. Analyzed for complex biantennary glycoforms and acceptors.CC BY-NC-ND · PubMed Central
Figure 8. No effect of glycosylation for binding affinity of FcRn in SPR analysis. (a) Sensorgrams of each glycoform. FcRn was directly immobilized on CM5 chip and glycoforms as analytes were injected by multi-cycle mode at six concentrations. Sensorgrams were fitted with steady-state equilibrium model. (b) Relative binding activities of FcRn. Error bars represent variation range of n = 2.
Figure 8. No effect of glycosylation for binding affinity of FcRn in SPR analysis. (a) Sensorgrams of each glycoform. FcRn was directly immobilized on CM5 chip and glycoforms as analytes were injected by multi-cycle mode at six concentrations. Sensorgrams were fitted with steady-state equilibrium model. (b) Relative binding activities of FcRn. Error bars represent variation range of n = 2.CC BY-NC-ND · PubMed Central
Figure 9. FcRn affinity chromatography showed longer retention by terminal galactosylation and sialylation. FcRn affinity chromatography utilized a human FcRn prepacked column. (a) Chromatograms and (b) Retention time of main peak. Terminal galactosylation and sialylation resulted in longer retention where mAb-HM and partially deglycosylated glycoforms showed the shortened retention. Error bar for mAb-ctrl represents SD of n = 6.
Figure 9. FcRn affinity chromatography showed longer retention by terminal galactosylation and sialylation. FcRn affinity chromatography utilized a human FcRn prepacked column. (a) Chromatograms and (b) Retention time of main peak. Terminal galactosylation and sialylation resulted in longer retention where mAb-HM and partially deglycosylated glycoforms showed the shortened retention. Error bar for mAb-ctrl represents SD of n = 6.CC BY-NC-ND · PubMed Central
Figure 10. Differential scanning calorimetry analysis of glycoforms showed thermal stability of CH2 domain was increased by terminal galactosylation and decreased in partially deglycosylated acceptors, terminally mannosylated mAb-HM, core defucosylated and terminal sialylated glycoforms. (a) Thermograms of each glycoform. (b) Transition peak of CH2 domain obtained from non-two-state curve fitting. (c) Thermal transition temperature Tm of CH2 domain obtained from curve fitting. Tm CH2 was significantly reduced in partially deglycosylated acceptors and terminally mannosylated mAb-HM. (d) Denaturation enthalpy ΔH of CH2 domain obtained from curve fitting showed significantly increased denaturing enthalpy by terminal galactosylation and decreased by core defucosylation and terminal sialylation. Error bars were generated based on variance of curve fitting using Origin software (c-d).
Figure 10. Differential scanning calorimetry analysis of glycoforms showed thermal stability of CH2 domain was increased by terminal galactosylation and decreased in partially deglycosylated acceptors, terminally mannosylated mAb-HM, core defucosylated and terminal sialylated glycoforms. (a) Thermograms of each glycoform. (b) Transition peak of CH2 domain obtained from non-two-state curve fitting. (c) Thermal transition temperature Tm of CH2 domain obtained from curve fitting. Tm CH2 was significantly reduced in partially deglycosylated acceptors and terminally mannosylated mAb-HM. (d) Denaturation enthalpy ΔH of CH2 domain obtained from curve fitting showed significantly increased denaturing enthalpy by terminal galactosylation and decreased by core defucosylation and terminal sialylation. Error bars were generated based on variance of curve fitting using Origin software (c-d).CC BY-NC-ND · PubMed Central
Figure 11. Intrinsic fluorescence spectroscopy (FS) analysis to measure transition temperature showed transition temperature was decreased in partially deglycosylated acceptors and terminally mannosylated mAb-HM glycoforms. (a) Barycentric mean (BCM) shift curve. (b) First derivative of BCM shift and (c) peak top temperatures as Tm FS for each glycoform. Tm FS was significantly reduced in partially deglycosylated acceptors and terminally mannosylated mAb-HM. Error bars represent variation range of n = 2.
Figure 11. Intrinsic fluorescence spectroscopy (FS) analysis to measure transition temperature showed transition temperature was decreased in partially deglycosylated acceptors and terminally mannosylated mAb-HM glycoforms. (a) Barycentric mean (BCM) shift curve. (b) First derivative of BCM shift and (c) peak top temperatures as Tm FS for each glycoform. Tm FS was significantly reduced in partially deglycosylated acceptors and terminally mannosylated mAb-HM. Error bars represent variation range of n = 2.CC BY-NC-ND · PubMed Central
Figure 12. Static light scattering analysis to measure aggregation propensity by temperature ramping showed aggregation temperature was increased by terminal galactosylation and decreased by terminal sialylation. (a) SLS counts of each glycoform. (b) Aggregation temperatures (Tagg) showed increased stability by terminal galactosylation and decreased stability by terminal sialylation. Core defucosylation also showed slightly decreased Tagg. Error bars represent variation range of n = 2.
Figure 12. Static light scattering analysis to measure aggregation propensity by temperature ramping showed aggregation temperature was increased by terminal galactosylation and decreased by terminal sialylation. (a) SLS counts of each glycoform. (b) Aggregation temperatures (Tagg) showed increased stability by terminal galactosylation and decreased stability by terminal sialylation. Core defucosylation also showed slightly decreased Tagg. Error bars represent variation range of n = 2.CC BY-NC-ND · PubMed Central
Figure 13. Static light scattering analysis to measure aggregation propensity by isothermal incubation at 65 °C showed aggregation speed was decreased by terminal galactosylation and increased by core defucosylation and terminal sialylation. (a) SLS counts for seven hours. (b) Time required to reach 2, 10 and 50% of maximum SLS counts for each glycoform. Error bars represent SD of n = 3. (c) JMP analysis: Scaled estimates of effect of glycosylation for relative time required to reach certain levels. Time required to reach 2, 10 and 50% of maximum SLS counts was converted into relative time to average of mAb-ctrl and statistically analyzed for complex biantennary glycoforms and acceptors.
Figure 13. Static light scattering analysis to measure aggregation propensity by isothermal incubation at 65 °C showed aggregation speed was decreased by terminal galactosylation and increased by core defucosylation and terminal sialylation. (a) SLS counts for seven hours. (b) Time required to reach 2, 10 and 50% of maximum SLS counts for each glycoform. Error bars represent SD of n = 3. (c) JMP analysis: Scaled estimates of effect of glycosylation for relative time required to reach certain levels. Time required to reach 2, 10 and 50% of maximum SLS counts was converted into relative time to average of mAb-ctrl and statistically analyzed for complex biantennary glycoforms and acceptors.CC BY-NC-ND · PubMed Central
Figure 14. Long-term forced degradation analyzed by size-exclusion chromatography showed significant increase of aggregation species in acceptors, mAb-HM and terminally galactosylated glycoforms but overall the same level of fragmentation among all glycoforms tested. (a) Chromatographic comparison of glycoforms after incubation for 17 days. (b) % increase of HMW species, with each aggregate-1 and aggregate-2 on top and bottom, respectively. (c) % increase of LMW species, with each fragment-1 and fragment-2 on bottom and top, respectively. n.t: not tested (b-c).
Figure 14. Long-term forced degradation analyzed by size-exclusion chromatography showed significant increase of aggregation species in acceptors, mAb-HM and terminally galactosylated glycoforms but overall the same level of fragmentation among all glycoforms tested. (a) Chromatographic comparison of glycoforms after incubation for 17 days. (b) % increase of HMW species, with each aggregate-1 and aggregate-2 on top and bottom, respectively. (c) % increase of LMW species, with each fragment-1 and fragment-2 on bottom and top, respectively. n.t: not tested (b-c).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 201

Metadata

Authors
Wada, R., Matsui, M., & Kawasaki, N.
Affiliations
  • Astellas Pharma (Japan) (JP)
  • Yokohama City University (JP)
Corresponding author
Wada, Ryuta
Venue
mAbs
Published
2018-12-10
Volume
11
Issue
2
Pages
350-372
ISSN
  • 1942-0862 (ISSN-L)
  • 1942-0870
OpenAlex
W2901207337
Cited by
186
References
77
Citations by year
2026: 27 · 2025: 25 · 2024: 20 · 2023: 18 · 2022: 26 · 2021: 34 · 2020: 26 · 2019: 10
FWCI
12.07
Type
journal article
Language
en
Open access
Locations
  • mAbs (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
funded by Astellas Pharma, Inc
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Keywords
N-glycosylation, IgG1 monoclonal antibody, glycoengineering, Fc effector functions, FcγRIIIa binding, antibody-dependent cellular cytotoxicity, C1q binding, FcRn binding, thermal stability, protein aggregation, core fucosylation, sialylation, galactosylation, mannosylation, N-glycan structure
MeSH terms
Antibodies, Monoclonal, Glycosylation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Polysaccharides, Protein Stability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.